BioLife Solutions (BLFS) Stock Price, News & Analysis

Company Overview

BioLife Solutions, Inc. develops and supplies products and services used in the development and commercial production of cell and gene therapies and other biologic medicines. Its offerings support the handling, preservation, storage and distribution of sensitive biological materials.

The company’s products include CryoStor and HypoThermosol preservation media, as well as CellSeal bags designed for cryogenic storage. BioLife also provides temperature-controlled storage and repository services for biological materials through its SciSafe business.

BioLife has expanded beyond its roots in biopreservation products to offer a broader portfolio for biopharmaceutical and life sciences customers. It serves customers in the United States and internationally, including therapy developers, biopharmaceutical companies and research organizations.

Key Stats

• Today's Range: $38.61 to $38.61
• 50-Day Range: $34.92 to $39.22
• 52-Week Range: $17.86 to $39.76
• Volume: N/A
• Average Volume: 1.18 million shs
• Market Capitalization: $1.89 billion
• P/E Ratio: 33.28
• Dividend Yield: N/A
• Price Target: $31.38
• Consensus Rating: Hold

BioLife Solutions Stock Analysis - MarketRank™

BioLife Solutions scored higher than 32% of companies evaluated by MarketBeat, and ranked 759th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

BioLife Solutions has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on no strong buy ratings, 1 buy rating, 10 hold ratings, and no sell ratings.

Downside Risk

BioLife Solutions has a consensus price target of $31.38, representing about 18.7% downside from its current price of $38.61.

Amount of Analyst Coverage

BioLife Solutions has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 433.33%

Earnings Growth

Earnings for BioLife Solutions are expected to grow by 433.33% in the coming year, from $0.03 to $0.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLife Solutions is 33.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLife Solutions is 33.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Price to Book Value per Share Ratio

BioLife Solutions has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.36% of the float of BioLife Solutions has been sold short.

Short Interest Ratio / Days to Cover

BioLife Solutions has a short interest ratio ("days to cover") of 4.33.

Change versus previous month

Short interest in BioLife Solutions has recently increased by 2.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLife Solutions does not currently pay a dividend.

Dividend Growth

BioLife Solutions does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

BioLife Solutions has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioLife Solutions this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioLife Solutions insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.20% of the stock of BioLife Solutions is held by insiders.

Percentage Held by Institutions

93.24% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:BLFS
• CIK: 834365
• Web: www.biolifesolutions.com
• Phone: (425) 402-1400
• Fax: 425-402-1433
• Employees: 440
• Year Founded: 1987

Price Target and Rating

• Average Price Target for BioLife Solutions: $31.38
• High Price Target: $34.00
• Low Price Target: $31.00
• Potential Upside/Downside: -18.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.16
• Trailing P/E Ratio: 33.28
• Forward P/E Ratio: 241.31
• P/E Growth: N/A
• Net Income: -$4.59 million
• Net Margins: 53.29%
• Pretax Margin: 6.28%
• Return on Equity: 2.70%
• Return on Assets: 2.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.69
• Quick Ratio: 7.14

Sales & Book Value

• Annual Sales: $106.69 million
• Price / Sales: 17.71
• Cash Flow: $0.23 per share
• Price / Cash Flow: 168.62
• Book Value: $7.72 per share
• Price / Book: 5.00

Miscellaneous

• Outstanding Shares: 48,923,000
• Free Float: 47,847,000
• Market Cap: $1.89 billion
• Optionable: Optionable
• Beta: 1.82